Treatment of Diabetic Neuropathy with Gamma-linolenic Acid. The Gamma-Linolenic Acid Multicenter Trial Group
Diabetes Care 1993 (Jan); 16 (1): 8–15
We entered 111 patients with mild diabetic neuropathy from seven centers into a randomized, double-blind, placebo-controlled parallel study of GLA at a dose of 480 mg/day. MNCV, SNAP, CMAP, hot and cold thresholds, sensation, tendon reflexes, and muscle strength were assessed by standard tests in upper and lower limbs.
Long-term Effects of Eicosapentaenoic Acid (EPA) on Diabetic Peripheral
Neuropathy and Serum Lipids in Patients with Type II Diabetes Mellitus
Journal of Diabetes and its Complications 1996; 10 (5): 280–287
The results of this study suggest that EPA-E has significant beneficial effects on diabetic neuropathy and serum lipids as well as other diabetic complications such as nephropathy and macroangiopathy.
The Use of Gamma-linolenic Acid in Diabetic Neuropathy
Agents Actions Suppl 1992; 37: 120–44
EF4 is an entirely new approach to the management of diabetic neuropathy. EF4 (providing gamma-linolenic acid or gamolenic acid, GLA) has been shown to reverse existing diabetic neuropathy in trials in seven centres. Diabetic animals and humans have a reduced ability to convert dietary linoleic acid to GLA.
Dietary Omega-3 Fatty Acid Deficiency and Visual Loss in Infant Rhesus Monkeys
J Clin Invest 1984 (Jan); 73 (1): 272–6
These results suggest that omega-3 fatty acids may be an essential nutrient, and that 22:6 omega 3 may have a specific function in the photoreceptor membranes of the retina.